Moderna Scores Another Cash-Rich Partnership For Its Preclinical Work
This article was originally published in The Pink Sheet Daily
The mRNA-focused company has inked a deal with Alexion for its work in rare diseases, promising plenty of cash in its future and further validation of its technology.
You may also be interested in...
Start-up companies raised $1.18 billion during the first quarter of 2014, up $2.8 million from last quarter’s total. Cancer was the leading therapy area involved in alliances.
The latest biotech to emerge from Flagship Ventures’ incubator is Moderna, which plans to focus on rare diseases in-house while out-licensing its technology for larger indications.
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.